Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

daratumumab

daratumumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Darzalex SOLUTION, INTRAVENOUS 100 mg/5 mL, 400 mg/20 mL      
Comments:

Drug reviewed for Outpatient Infusion (updated May 7, 2021)

DARATUMUMAB (original brand names Darzalex and Darzalex Faspro)

Payer Preferred Agent Notes
BCBS Darzalex  
Medicare Darzalex or Darzalex Faspro Similar margins
Medicaid Darzalex  
Tricare --  
Commercial (Non-BCBS) Check with payer for preferred agent; check with Finance for margin*
Lowest cost (self-pay/HH employee) Darzalex  

*In many cases, the “originator” product provides the best margin with non-BCBS commercial payers.

Restricted to oncology.  Defer infusion to outpatient setting if possible.

Outpatient daratumumab cycle 3+ rapid infusion protocol available for adults. daratumumab cycle 3+ rapid infusion (adults)

 

Reviewed: 22 March 2016, October 22, 2019.

Chemotherapy Dose Rounding Chart

Last updated: May. 18, 2021
  • Formulary, Not Routinely Stocked: Darzalex --> 100 mg/5 mL, 400 mg/20 mL






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved